SAPIEN 3 valve, fenestrated stent graft and the HeartMate3 LVAD
PMCC has tested the SAPIEN 3 valve, fenestrated stent graft and the HeartMate3 LVAD (Photo: The Globe and Mail)

"We pride ourselves on being the hospital that introduces new technologies to the country's healthcare system," says Dr. Vivek Rao, Head of the Division of Cardiovascular Surgery at the Peter Munk Cardiac Centre (PMCC), and the centre's Chair in Advanced Cardiac Therapeutics.

When it comes to bringing broken hearts back from the brink, the PMCC is a global leader.

The PMCC is a go-to proving ground for the latest devices that are rapidly changing the treatment of heart disease. It's often on the short list when industry partners seek to test new devices on patients who often have no other safe, viable therapy alternatives.

Call it the cutting-edge technology that can reduce the "cutting" involved in surgery.

"The device field is rapidly evolving as the technology improves, and every three to four years a new device is introduced into the market," says Dr. Rao.

New devices tested at the centre save lives. They also transform what were once major surgeries into much safer procedures, involving smaller incisions and less recovery time.


PMCC Magazine - 2018 

This is the fourth Peter Munk Cardiac Centre magazine published by The Globe and Mail. Flip through its (digital) pages to read more about a day in the life of PMCC, game-changing devices, precision medicine and a tribute to our namesake, Peter Munk. The magazine is now available online​.

​​

Share This Story

Share Tweet Email